Business Segments · Exit and other-related costs
North American Pharmaceutical — Exit and other-related costs
McKesson North American Pharmaceutical — Exit and other-related costs decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ3 2024
Last reportedQ4 2025
Rolls up toBusiness Exit Costs
How to read this metric
Higher costs suggest significant strategic shifts or business consolidation, whereas lower costs indicate operational stability.
Detailed definition
This metric captures costs associated with exiting specific business activities, facilities, or geographic markets withi...
Peer comparison
Often categorized under restructuring or exit costs in the financial statements of large-scale distribution companies.
Metric ID:
mck_segment_north_american_pharmaceutical_exit_and_other_related_costsHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | -$1.00M | $1.00M | $1.00M | $0.00 |
| QoQ Change | — | +200.0% | +0.0% | -100.0% |
| YoY Change | — | — | +200.0% | -100.0% |
Range-$1.00M – $1.00M
Avg YoY Growth+50.0%
Median YoY Growth+50.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — exit and other-related costs?
- McKesson (MCK) reported north american pharmaceutical — exit and other-related costs of $0.00 in Q4 2025.
- What does north american pharmaceutical — exit and other-related costs mean?
- Costs incurred from closing down specific business operations or facilities within the North American Pharmaceutical segment.